Bayer, Regeneron anti-blindness drug Eylea shown to work at higher dose, longer intervals
Advertisement
Frankfurt: Bayer said on Thursday that its anti-blindness treatment Eylea, jointly developed with Regeneron, was shown to work as well when given at a higher dose at a longer interval between injections.
Eylea, which is normally given at 2 milligrams every eight weeks, was shown in two late-stage trials to be as effective when given at 8 mg at longer intervals, without any additional safety issues, the German company said in a statement.
The results will help Bayer compete with Roche, while rival drug Vabysmo was launched this year. The Swiss drugmaker is seeking to win over patients with longer intervals between injections.
Read also: Bayer unveils drug for CKD associated with diabetes under brand name Kerendia
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.